Antiplatelet activity and TNF-α release inhibition of phthalimide derivatives useful to treat sickle cell anemia

Autor: Isabela Junqueira Oliveira, Sisi Marcondes, Karina Pereira Barbieri, Iracilda Zeppone Carlos, Diego Eidy Chiba, ManChin Chung, Rafael Consolin Chelucci, Jean Leandro dos Santos, Maria Elisa Lopes-Pires, Marisa Campos Polesi
Přispěvatelé: Universidade Estadual Paulista (Unesp), Universidade Estadual de Campinas (UNICAMP)
Rok vydání: 2019
Předmět:
Zdroj: Scopus
Repositório Institucional da UNESP
Universidade Estadual Paulista (UNESP)
instacron:UNESP
ISSN: 1554-8120
1054-2523
DOI: 10.1007/s00044-019-02371-z
Popis: Made available in DSpace on 2019-10-06T15:44:48Z (GMT). No. of bitstreams: 0 Previous issue date: 2019-08-01 Sickle Cell Anemia (SCA) is one of the most prevalent hereditary hematological diseases worldwide. The disease is characterized by chronic inflammation, hypercoagulable state, and pro-thrombotic profile, which lead the vaso-occlusive process. In this work, we described the antiplatelet activity and the ability to reduce tumor necrosis factor-alpha (TNF-α) levels of phthalimide derivatives. All compounds inhibited platelet aggregation induced by collagen and adenosine diphosphate, at levels ranging from 26.0 to 74.2% and 30.7 to 79.6%, respectively. The compounds exhibited reduced bleeding time compared to acetylsalicylic acid (ASA). Moreover, compounds 4c and 10c inhibited TNF-α levels at 73.5% and 65.0%, respectively. These findings suggest that phthalimide derivatives 4c and 10c are promising lead compounds useful to prevent vaso-occlusion and inflammation associated with the sickle cell anemia. School of Pharmaceutical Sciences São Paulo State University (UNESP) Faculty of Medical Science State University of Campinas (Unicamp) Campinas School of Pharmaceutical Sciences São Paulo State University (UNESP)
Databáze: OpenAIRE